- Home
- ENTA vs ESGL Comparison
ENTA vs ESGL Comparison
Compare ENTA & ESGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- ESGL
- Stock Information
- Founded
- ENTA 1995
- ESGL 1999
- Country
- ENTA United States
- ESGL Singapore
- Employees
- ENTA N/A
- ESGL N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- ESGL
- Sector
- ENTA Health Care
- ESGL
- Exchange
- ENTA Nasdaq
- ESGL Nasdaq
- Market Cap
- ENTA 164.6M
- ESGL 154.3M
- IPO Year
- ENTA 2013
- ESGL N/A
- Fundamental
- Price
- ENTA $7.84
- ESGL $3.98
- Analyst Decision
- ENTA Strong Buy
- ESGL
- Analyst Count
- ENTA 5
- ESGL 0
- Target Price
- ENTA $20.20
- ESGL N/A
- AVG Volume (30 Days)
- ENTA 164.6K
- ESGL 26.3K
- Earning Date
- ENTA 08-11-2025
- ESGL 09-23-2025
- Dividend Yield
- ENTA N/A
- ESGL N/A
- EPS Growth
- ENTA N/A
- ESGL N/A
- EPS
- ENTA N/A
- ESGL N/A
- Revenue
- ENTA $64,806,000.00
- ESGL $6,099,784.00
- Revenue This Year
- ENTA N/A
- ESGL N/A
- Revenue Next Year
- ENTA $1.65
- ESGL N/A
- P/E Ratio
- ENTA N/A
- ESGL N/A
- Revenue Growth
- ENTA N/A
- ESGL N/A
- 52 Week Low
- ENTA $4.09
- ESGL $0.90
- 52 Week High
- ENTA $13.37
- ESGL $4.00
- Technical
- Relative Strength Index (RSI)
- ENTA 45.61
- ESGL 74.09
- Support Level
- ENTA $7.28
- ESGL $3.42
- Resistance Level
- ENTA $8.86
- ESGL $4.00
- Average True Range (ATR)
- ENTA 0.53
- ESGL 0.29
- MACD
- ENTA -0.18
- ESGL 0.08
- Stochastic Oscillator
- ENTA 29.63
- ESGL 98.62
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.